CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Supportive care in myeloma-when treating the clone alone is not enough.
Supportive care in myeloma-when treating the clone alone is not enough.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
近几十年来,多发性骨髓瘤患者总生存期延长。随着CAR-T 细胞疗法和T细胞衔接型双特异性抗体等T细胞重定向疗法出现,预计这一趋势还将继续。但尽管治疗有所改善,治疗相关不良事件仍会损害患者生活质量,凸显优化支持治疗策略、最大程度改善治疗结局的必要性。支持治疗不仅关系患者福祉,也影响治疗依从性,进而可能转化为长期疾病控制。本文介绍:(a)骨病预防;(b)风险适配的血栓预防策略;(c)管理靶向G蛋白偶联受体C类5组D型的T细胞重定向疗法所致靶向肿瘤外毒性;(d)感染预防,重点讨论T细胞重定向治疗期间的感染。
The overall survival in patients with multiple myeloma has increased over recent decades. This trend is anticipated to further advance with the emergence of T-cell-redirecting therapies, including chimeric antigen receptor T-cell (CAR T) therapy and T-cell-engaging bispecific antibodies.
Despite these therapeutic improvements, treatment-related adverse events impede quality of life. This underscores the imperative of optimizing supportive care strategies to maximize treatment outcomes. Such optimization is crucial not only for patient well-being but also for treatment adherence, which may translate into long-term disease control.
We here describe a) how to prevent bone disease, b) a risk-adapted thrombosis prophylaxis approach, c) the management of on-target, off-tumor toxicity of G-protein-coupled receptor class C group 5 member D-targeting T-cell-redirecting therapies, and d) infectious prophylaxis, with a focus on infections during T-cell-redirecting therapies.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。